Apoptosis: Targets in pancreatic cancer

被引：119
作者：
Sabine Westphal
Holger Kalthoff
机构：
[1] Department of Molecular Oncology, Clinic for General/Thoracic Surgery, University of Kiel, 24105 Kiel
来源：
Molecular Cancer | / 2卷 / 1期
关键词：
Apoptosis; Oncologic therapies; Pancreatic cancer;
D O I：
10.1186/1476-4598-2-6
中图分类号：
学科分类号：
摘要：
Pancreatic adenocarcinoma is characterized by poor prognosis, because of late diagnosis and lack of response to chemo- and/or radiation therapies. Resistance to apoptosis mainly causes this insensitivity to conventional therapies. Apoptosis or programmed cell death is a central regulator of tissue homeostasis. Certain genetic disturbances of apoptotic signaling pathways have been found in carcinomas leading to tumor development and progression. In the past few years, the knowledge about the complex pathways of apoptosis has strongly increased and new therapeutic approaches based on this knowledge are being developed. This review will focus on the role of apoptotic proteins contributing to pancreatic cancer development and progression and will demonstrate possible targets to influence this deadly disease. © 2003 Westphal and Kalthoff; licensee BioMed Central Ltd.
引用
收藏
页数：14
相关论文
共 160 条
[11]  
Igney F.H., Krammer P.H., Death and anti-death: Tumour resistance to apoptosis, Nature Rev. Cancer, 2, pp. 277-288, (2002)
[12]  
Miyashita T., Reed J.C., Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line, Blood, 81, pp. 151-157, (1993)
[13]  
Korsmeyer S.J., Bcl-2 initiates a new category of oncogenes: Regulators of cell death, Blood, 80, pp. 879-886, (1992)
[14]  
Hager J.H., Hanahan D., Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis, Ann. N. Y. Acad. Sci., 887, pp. 150-163, (1999)
[15]  
Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S., The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis, Cell, 66, pp. 233-243, (1991)
[16]  
Suda T., Takahashi T., Golstein P., Nagata S., Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family, Cell, 75, pp. 1169-1178, (1993)
[17]  
Krammer P.H., Galle P.R., Moller P., Debatin K.M., CD95 (APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells, Adv. Cancer Res., 75, pp. 251-273, (1998)
[18]  
Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., Krammer P.H., Walczak H., FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2, Immunity, 12, pp. 599-609, (2000)
[19]  
Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E., Two CD95 (APO-1/Fas) signaling pathways, EMBO J., 17, pp. 1675-1687, (1998)
[20]  
Zamzami N., Kroemer G., The mitochondrion in apoptosis: How Pandora's box opens, Nature Rev. Mol. Cell Biol., 2, pp. 67-71, (2001)
12345678910